The test is marketed under the name Therascreen® PITX2 RGQ PCR Kit (QIAGEN GmbH, Hilden, Germany) and targets methylation changes at PITX2 gene which in several studies have been shown to have prognostic [86, 87] and predictive [88] significance in breast cancer. Here, PITX2 is linked to breast cancer.